ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1719

Periostin May Promote Productin of Extracellular Matrix By Modulating TGF-β Signaling in Human Skin Fibroblasts

Yukie Yamaguchi1, Noriko Koumitsu1, Kazuhiko Arima2, Kenji Izuhara2 and Michiko Aihara3, 1Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Biomolecular Sciences, Saga Medical School, Saga, Japan, 3Department of Environmental-immuno Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: fibrosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic sclerosis (SSc) results in significant morbidity and mortality due to organ fibrosis characterized by increased deposition of extracellular matrix (ECM). Periostin is one of the matricellular proteins, a class of ECM-related molecules defined by their ability to modulate cell–matrix interactions. Recent studies revealed that periostin serves as a critical regulator of wound healing, epithelial mesenchymal transition, and fibrosis. We previously reported elevated serum periostin levels in SSc patients which correlated with severity of skin sclerosis. However, the pathogenic role of periostin in fibrosis has not been well elucidated. In this study, we further examined the role of periostin on transforming growth factor-β (TGF-β) signaling mediating fibrosis.

Methods: Periostin levels in skin and lung primary fibroblasts obtained from SSc patients were first determined. To enhance the function of periostin, we overexpressed periostin in human skin fibroblasts and examined protein levels of ECM proteins, α-smooth muscle actin (α-SMA), matrix metalloproteinases (MMPs) in the presence or absence of TGF-β by immunoblotting. Interaction of periostin with TGF-β receptors (TGF-βRI, TGF-βRII) was assessed by immunoprecipitation assay. Furthermore, effects of periostin to Smad proteins following TGF-β stimulation were also evaluated.

Results: Periostin was strongly expressed in skin and lung primary fibroblasts obtained from SSc patients compared with healthy subjects. Although single stimulation of recombinant periostin (rP) did not increase ECM protein levels, rP-treated fibroblasts and periostin overexpressed fibroblasts produced significant ECM proteins in the presence of TGF-β compared to respective control fibroblasts stimulated with TGF-β alone. Overexpression of periostin enhanced the induction of α-SMA in the presence of TGF-β and increased expression of MMP-1, which is reported to associate TGF-β activation. In addition, phosphorylation of Smad 2/3 by TGF-β was not affected by periostin, but a level of Smad 7, a TGF-β-inducible inhibitor of TGF-β signaling, was reduced in periostin expressed fibroblasts stimulated with TGF-β.  

Conclusion: Periostin may contribute to fibrosis by enhancing TGF-β signaling via TGF-β activation and Smad 7 inhibition, which leads to further ECM deposition and periostin generation. Periostin may be a therapeutical target molecule mediating fibrosis.


Disclosure:

Y. Yamaguchi,
None;

N. Koumitsu,
None;

K. Arima,
None;

K. Izuhara,
None;

M. Aihara,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/periostin-may-promote-productin-of-extracellular-matrix-by-modulating-tgf-%ce%b2-signaling-in-human-skin-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology